EE86 Cost-Effectiveness Analysis of Axicabtagene Ciloleucel, Lisocabtagene Maraleucel, and Tisagenlecleucel CAR T-Cell Therapies for Treatment of Relapsed or Refractory Large B-Cell Lymphoma (LBCL)
Jun 1, 2023, 00:00 AM
10.1016/j.jval.2023.03.390
https://www.valueinhealthjournal.com/article/S1098-3015(23)00490-4/fulltext
Section Title :
Section Order :
11774
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00490-4&doi=10.1016/j.jval.2023.03.390